Drug Details
| General Information of the Drug (ID: DR1229) | ||||
|---|---|---|---|---|
| Name |
PP242
|
|||
| Synonyms |
TORKinib
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Colon cancer [ICD-11: 2B90] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C16H16N6O
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(N3)C=CC(=C4)O)N
|
|||
| InChI |
1S/C16H16N6O/c1-8(2)22-16-13(15(17)18-7-19-16)14(21-22)12-6-9-5-10(23)3-4-11(9)20-12/h3-8,20,23H,1-2H3,(H2,17,18,19)
|
|||
| InChIKey |
MFAQYJIYDMLAIM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1092351-67-1
|
|||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | RICTOR | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Lysosomal membrane permeabilization | ||||
| In-vitro Model | Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | ||
| ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | |||
| A-498 | CVCL_1056 | Renal cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells. | |||||
| β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Daunorubicin | Streptomyces peucetius | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | ||
| SUP-B15 | CVCL_0103 | B acute lymphoblastic leukemia | Homo sapiens | |||
| JeKo-1 | CVCL_1865 | Mantle cell lymphoma | Homo sapiens | |||
| NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
PP242 effectively eliminated this deleterious side effect of DNR and synergistically enhanced the anticancer ability of DNR treatment. PP242, especially in combination with DNR, exerts significant antileukemia effects. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | PAS-kinase (PASK) | Molecule Info | [4] | |
| Serine/threonine-protein kinase mTOR (mTOR) | Molecule Info | [4] | ||
| KEGG Pathway | ErbB signaling pathway | Click to Show/Hide | ||
| 2 | HIF-1 signaling pathway | |||
| 3 | mTOR signaling pathway | |||
| 4 | PI3K-Akt signaling pathway | |||
| 5 | AMPK signaling pathway | |||
| 6 | Insulin signaling pathway | |||
| 7 | Thyroid hormone signaling pathway | |||
| 8 | Adipocytokine signaling pathway | |||
| 9 | Type II diabetes mellitus | |||
| 10 | Pathways in cancer | |||
| 11 | Proteoglycans in cancer | |||
| 12 | MicroRNAs in cancer | |||
| 13 | Glioma | |||
| 14 | Prostate cancer | |||
| 15 | Acute myeloid leukemia | |||
| 16 | Central carbon metabolism in cancer | |||
| 17 | Choline metabolism in cancer | |||
| Panther Pathway | Hypoxia response via HIF activation | Click to Show/Hide | ||
| 2 | Interleukin signaling pathway | |||
| Pathwhiz Pathway | Leucine Stimulation on Insulin Signaling | Click to Show/Hide | ||
| Pathway Interaction Database | IL4-mediated signaling events | Click to Show/Hide | ||
| 2 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 3 | IL12-mediated signaling events | |||
| 4 | CDC42 signaling events | |||
| 5 | LKB1 signaling events | |||
| 6 | Regulation of Telomerase | |||
| 7 | mTOR signaling pathway | |||
| 8 | CXCR4-mediated signaling events | |||
| 9 | EGFR-dependent Endothelin signaling events | |||
| 10 | IL2 signaling events mediated by PI3K | |||
| 11 | IFN-gamma pathway | |||
| 12 | ErbB1 downstream signaling | |||
| 13 | ErbB2/ErbB3 signaling events | |||
| 14 | CXCR3-mediated signaling events | |||
| 15 | Class I PI3K signaling events mediated by Akt | |||
| Reactome | PIP3 activates AKT signaling | Click to Show/Hide | ||
| 2 | Macroautophagy | |||
| 3 | mTORC1-mediated signalling | |||
| 4 | HSF1-dependent transactivation | |||
| 5 | CD28 dependent PI3K/Akt signaling | |||
| 6 | VEGFR2 mediated vascular permeability | |||
| 7 | TP53 Regulates Metabolic Genes | |||
| 8 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| WikiPathways | ErbB Signaling Pathway | Click to Show/Hide | ||
| 2 | Senescence and Autophagy in Cancer | |||
| 3 | Interferon type I signaling pathways | |||
| 4 | Insulin Signaling | |||
| 5 | EGF/EGFR Signaling Pathway | |||
| 6 | Wnt Signaling Pathway Netpath | |||
| 7 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 8 | Cardiac Hypertrophic Response | |||
| 9 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||
| 10 | PIP3 activates AKT signaling | |||
| 11 | Polycystic Kidney Disease Pathway | |||
| 12 | Alpha 6 Beta 4 signaling pathway | |||
| 13 | BDNF signaling pathway | |||
| 14 | Oncostatin M Signaling Pathway | |||
| 15 | Prostate Cancer | |||
| 16 | TSLP Signaling Pathway | |||
| 17 | FSH signaling pathway | |||
| 18 | Leptin signaling pathway | |||
| 19 | TSH signaling pathway | |||
| 20 | RANKL/RANK Signaling Pathway | |||
| 21 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
| 22 | Integrated Breast Cancer Pathway | |||
| 23 | SREBP signalling | |||
| 24 | Signaling by Insulin receptor | |||
| 25 | Costimulation by the CD28 family | |||
| 26 | Type II diabetes mellitus | |||
| 27 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 28 | TOR Signaling | |||
| 29 | AMPK Signaling | |||
